BioMarin Pharmaceutical
Global rare disease biotechnology company developing genetically targeted therapies for inherited conditions.
BioMarin Pharmaceutical – Company OverviewBioMarin Pharmaceutical Inc. is a publicly traded rare disease biotechnology company headquartered in San Rafael, California, founded in 1997 and listed on NASDAQ under the ticker BMRN. The company specializes in developing and commercializing medicines for people living with genetically defined conditions, with a core scientific focus on enzyme replacement therapies (ERTs) and molecular mechanisms underlying rare inherited diseases.
BioMarin has nine approved commercial therapies spanning conditions such as mucopolysaccharidosis (MPS I, IV A, and VI), phenylketonuria (PKU), neuronal ceroid lipofuscinosis type 2, severe hemophilia A, and achondroplasia. It was the first company to provide therapeutics for both MPS I and PKU. Its portfolio includes VIMIZIM, NAGLAZYME, ALDURAZYME, BRINEURA, KUVAN, PALYNZIQ, ROCTAVIAN, and VOXZOGO, alongside a clinical and preclinical pipeline.
BioMarin operates globally with offices and facilities across the United States, South America, Asia, and Europe, and employs approximately 3,221 people. The company has demonstrated strong revenue growth, reporting $2.854 billion in 2024 revenue (up ~18% year-over-year) and $3.221 billion in 2025, with recent growth driven significantly by VOXZOGO for achondroplasia.
Given BioMarin's deep expertise in genetically defined rare diseases, enzyme replacement, and gene therapy (ROCTAVIAN), innovations in genomics, targeted drug delivery, or rare disease diagnostics are directly relevant to its core research and commercial operations.
Ideas that could help BioMarin Pharmaceutical
- PKU Precision Dosage Engine
A clinical decision support tool that predicts a PKU patient's response to sapropterin by mapping their PAH genotype to a functional activity landscape. The engine suggests personalized treatment protocols while accounting for regional genetic variability and the presence of rare mutations.
Why it helps: As a producer of PKU treatments, they can use this data to better identify which patient cohorts are most likely to respond to specific therapies.
- Mitochondria-Targeted Exosome Drug Delivery for Methylmalonic Acidemia Neuroprotection
An engineered exosome delivery vehicle loaded with antioxidant or enzyme-replacement cargo, surface-functionalized to cross the blood-brain barrier and deposit payload directly into neuronal mitochondria, targeting the root cause of MMAemia-associated brain injury.
Why it helps: Established leader in rare enzyme-deficiency therapies with existing neurology infrastructure; an exosome BBB-delivery platform would extend their rare metabolic disease pipeline into CNS-hard-to-reach indications.